Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors
- 1 November 2001
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 12 (11) , 1643-1649
- https://doi.org/10.1023/a:1013180903805
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Coadministration of Cyclosporine Strongly Enhances the Oral Bioavailability of DocetaxelJournal of Clinical Oncology, 2001
- P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugsAdvanced Drug Delivery Reviews, 1999
- Oral chemotherapy: rationale and future directions.Journal of Clinical Oncology, 1998
- Patient preferences for oral versus intravenous palliative chemotherapy.Journal of Clinical Oncology, 1997
- Clinical phase I and pharmacokinetic trial of vinorelbine administered as single intravenous bolus every 21 days in cancer patientsInvestigational New Drugs, 1996
- Relative bioavailability of two oral formulations of navelbine in cancer patientsBiopharmaceutics & Drug Disposition, 1994
- Vinorelbine: a horse of a different color?Journal of Clinical Oncology, 1994
- Individual Variation in First-Pass MetabolismClinical Pharmacokinetics, 1993
- Oral administration of [3H]navelbine in patientsAnti-Cancer Drugs, 1991
- Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and ratsCancer Chemotherapy and Pharmacology, 1986